- HDSA Research
- Grant Applications
Research News & Reports
- Raptor Pharmaceuticals Announces Phase 2/3 Clinical Trial Results with Cysteamine (RP103) in Huntington’s disease
- Results of Phase 2 HD prevention and biomarker study (PRECREST) using high-dose of creatine published
- NIH announces first funding opportunities for the BRAIN Initiative
- Teva Pharmaceutical Industries to Purchase Huntexil from Neurosearch
- Postcard from CHDI February 2011
- HD Insights Volume 3
- Auspex Pharmaceuticals Plans Phase III Clinical Trial for Chorea in HD Patients
Research News Archive
- GABA stell cells
- proteomic analysis
- Methylene Blue
- A New Gene Silencing Technique Enters the Pipeline
- Hayden Study NMDAR Memantine
- MermaiHD ACR-16 (Huntexil) Trial Results
- MermaiHD Data Adjustment
- SIRT2 inhibition not promising
- Ray Truant and Colleagues Publish Promising Findings
- Melatonin Delays Onset of HD in Mouse Model
- Track-HD Dec 2012 Announcement
- New Prion Research Focuses Attention on the UPR in HD
- CIRM Awards $18 Million to UC-Davis for HD Stem Cell Research
- ENCODE Study finds "genetic switches"
- Video Postcard from CHDI 2012 Conference
- Researchers Restore Neuron Function using iPSCs
- Lundbeck CHDI Collaboration
- Video Postcards from Prauge
- EHDN Nightly News
- HDL2 News Page
- Steven Hersch Interview
- Siena Biotech
- Prana Planning
- Mechanism Matters
- Toxic Protein Form
- Roche and ISIS form HD Alliance
- FDA Selects HD for Patient-Focused Drug Development
- ASO treatment delivered to Alzheimer's patients in Phase I Study
- Prana Completes Phase 2 Huntington's Disease Trial with PBT2
- Omeros Phase I OMS824 Trial Results Positive
- Pharmacological Treatment of Chorea in HD Clinical Practice
- Research Webinar Series
- Clinical Trials
- HDBuzz Research News
- HD Gene Symposium: 20 Years
- Therapies in Pipeline
- Research Conferences
- Scientific Advisory Board
- Research Pipeline
- Stem Cells
- HD Insights
- HD Glossary
- Links to Other Research
- Reports Library
- Research Investors Reports
GM1 Restores Motor Function in the YAC128 Mouse
Dr. Simonetta Sipione
Researchers at the University of Alberta and McMaster University have reversed motor symptoms in the YAC128 HD mice by a continuous infusion of the ganglioside GM1 into the ventricles of the brain. Other treatments in the pipeline have delayed onset or slowed progression in the HD mice; this is the first treatment to actually bring about improvement.
GM1 (monosialotetrahexosylganglioside) is a lipid or fat that is normally found in the brain and is part of the outer covering or membrane of neurons. By influencing and interacting with membrane proteins, gangliosides affect the activity of a number of tyrosine kinase and neurotransmitter receptors and ion channels and are involved in cell to cell interaction. GM1 plays an especially important role in cell signaling and cell to cell interaction.
In a 2010 study, Dr. Simonetta Sipione and colleagues from the University of Alberta showed that the synthesis of GM1 is reduced in a variety of models of HD as well as in fibroblasts (cells found in connective issue) from HD patients. They also showed that striatal cells with reduced GM1 are more vulnerable to apoptosis (programmed cell death) and that restoring levels of GM1 reversed the vulnerability. Administration of GM1 to striatal cells resulted in the activation of the prosurvival kinase AKT. The PI3K/AKT pathway is known to be impaired in HD. They also found that the HD protein experienced increased phosphorylation but exactly how and where could not be determined because of the methodology used. Given these findings and the known importance of GM1 in the brain, restoration of GM1 thus appeared to be a promising therapeutic strategy.
In the current study, principal investigator Dr. Sipione and her team worked with Dr. Ray Truant and a colleague from McMasters University as well as others to test GM1 as a potential treatment in five month old YAC128 mice. At that point, the mice have marked motor impairment. GM1 was continuously infused into the ventricles of the mice for four weeks. After two weeks, improvement in motor skills began to be noted with a complete reversal of the impairment occurring, as measured by challenging rotarod, ladder climbing and narrow balance beam tests. The improvements lasted an additional two weeks after discontinuation of the treatment but by four weeks, motor skills had declined to pre-treatment levels.
"We didn't expect to see such dramatic changes after administering this therapy," said Dr. Sipione. "We expected to see improvement, but not complete restoration of motor skills. When we saw this, we were jumping with excitement in the lab. This is very promising and should give hope to those with Huntington disease. I think it's a treatment that deserves to go to clinical trials because it could have huge potential."
The researchers found that treatment with GM1 restores normal levels of DARPP-32 (dopamine and cAMP-regulated neuronal phosphoprotein) expression. DARPP-32 is a protein involved in dopamine signaling. Decreased DARPP-32 expression is an early sign of neuronal dysfunction in both the R6/2 and the YAC128 mouse models of HD. The restoration of normal motor behavior in the mice treated with GM1 correlated with the increased striatal expression of DARPP-32.
There are likely other mechanisms involved in the positive results but the primary mechanism is likely to be the phosphorylation of serines 13 and 16 on the HD protein. Research that we covered two years ago identified phosphorylation of these two places on the HD protein as a potential therapeutic strategy.
Phosphorylation is a post-translational (ie, after the protein is made) modification of a protein in which a phosphate group is added to a serine, threonine, or tyrosine residue by a kinase (an enzyme that transfers phosphate groups). Proteins are commonly regulated through phosphorylation.
In a landmark study, Dr. William Yang and colleagues in his lab engineered two types of BAC transgenic (HD) mice and followed them for a year. In one type of HD mouse, serines 13 and 16 were mutated to aspartate. This mimics phosphorylation and essentially makes it efficient and permanent throughout the life of the mouse. In the other type of HD mouse, the serines were mutated to alanine which cannot be phosphorylated.
The mice with the mutation that mimics phosphorylation did not demonstrate the motor and behavioral problems that indicate early neuronal dysfunction nor did they experience neurodegeration. In addition, no large aggregates were detected as would normally be found. These aggregates are a hallmark of the disease so their absence can be a good sign. However, if the disease process is present and the HD protein begins accumulatingin the cells, the aggregated form appears to be less toxic than the soluble form.
"Our study identified a critical molecular switch which lies next to the polyQ mutation in the huntingtin protein," Dr. Yang said. "We were surprised to find that subtle modification of only two serine residues in this very large protein can prevent the onset of disease. This finding suggests an exciting new avenue to develop therapeutics for Huntington's disease."
The current study by Dr. Sipione and colleagues takes a major step forward by finding a brain chemical which phosphorylates serines 13 and 16 in addition to its other actions. "I think it is really exciting to know that there are evidence for chemicals that can boost phosphorylation of the mutant huntingtin at serines 13 and 16 and markedly improve the behavioral deficits in HD mice. This is the first proof-of-concept that such molecular switch could be altered in a beneficial way in vivo by a drug-like molecule." said Dr. Yang about the current study.
In a study covered two years ago, Dr. Joan Steffan and colleagues raised a concern about phosphorylation as a potential treatment. They speculated that such a treatment would need to be offered early, while the protein clearance machinery is still working at top form since phosphorylation enhances nuclear localization. When the machinery becomes less efficient with aging and exposure to the HD protein, the treatment could actually become harmful by speeding up the accumulation of the HD protein in the nucleus of the cell. This hypothesis is based on research with cell models and drosphila (fruitfly) models of HD and needs to be investigated in mammals. Dr. Yang recommends that a longer study be completed in the YAC128
or BACHD mice to examine the effects of long term administration, see if GM1 administration prevents neurodegeneration and learn whether or not it could exert any harmful effects at a certain point in the disease process.
Dr. Sipione and her group are interested in seeing GM1 go to clinical trials as soon as possible and expect this to happen in the next year or two. They are hoping to do a pilot study at the University of Alberta.
Administration of GM1 would require the use of a brain infusion pump or an intrathecal pump. These devices are available through Medtronics.
GM1 has been in clinical trials for Parkinson’s disease for some time. A five year open label study reported a good safety profile and possible benefits. In 2002, a pilot study involving ventricular infusion into the brains of five Alzheimer’s patients was published. The patients did well and some benefits were reported.
Dr. Ray Truant’s group will be looking for drugs with the safe effect as GM1 but which might be easier to administer. In an interview with the Hamilton Spectator Dr. Truant said, “I’m optimistic in that I think there’s going to be, in the three-to-five-year timeframe, a major advancement in clinical trials as a result of this,” he said. “It may not be GM1, but it may be a drug that acts like GM1.”
*Alba Di Pardoa, Vittorio Maglione, Melanie Alpaugh, Melanie Horkey, Randy S. Atwal, Jenny Sassone, Andrea Ciammola, Joan S. Steffan, Karim Fouad, Ray Truant, and Simonetta Sipione “Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice.” Proceedings of the National Academy of Sciences Epub ahead of print February 13, 2012.
Xiaofeng Gu, Erin R. Greiner, Rakesh Mishra, Ravindra Kodali, Alex Osmand, Steven Finkbeiner, Joan S. Steffan, Leslie Michels Thompson, Ronald Wetzel, and X. William Yang. “Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice.” Neuron 2009 Dec 24;64:828-840.
Vittorio Maglione, Paolo Marchi, Alba Di Pardo, Susanne Liingrell, Melanie Horkey, Emily Tidmarsh, and Simonetta Sipione. “Impaired Ganglioside Metabolism in Huntington's Disease and Neuroprotective Role of GM1.” The Journal of Neuroscience, 17 March 2010, 30(11): 4072-4080.
Jay S. Schneider, Stephanie Sendek, Constantine Daskalakis, and Franca Cambi. “GM1 ganglioside in Parkinson's disease: Results of a five year open study.” Journal of the Neurological Sciences, 15 May 2010,292(1): 45-31.
Lars Svennerholm, Görel Bråne, Ingvar Karlsson, Annika Lekman, Ingalill Ramström, Carsten Wikkelsö. “Alzheimer Disease – Effect of Continuous Intracerebroventricular Treatment with GM1 Ganglioside and a Systematic Activation Programme.” Dementia and Geriatric Cognitive Disorders 2002;14:128-136.
Leslie Michels Thompson, Charity T. Aiken, Linda S. Kaltenbach, Namita Agrawal, Katalin Illes, Ali Khoshnan, Marta Martinez-Vincente, Montserrat Arrasate, Jacqueline Gire O’Rourke, Hasan Khashwji, Tamas Lukacsovich, Ya-Zhen Zhu,1 Alice L. Lau, Ashish Massey, Michael R. Hayden, Scott O. Zeitlin, Steven Finkbeiner, Kim N. Green, Frank M. LaFerla, Gillian Bates, Lan Huang, Paul H. Patterson, Donald C. Lo, Ana Maria Cuervo, J. Lawrence Marsh, and Joan S. Steffan. “IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome.” The Journal of Cell Biology 2009 Dec 28;187(7):1083-99.
Danielle Wong, “McMaster researchers reverse Huntington’s disease in mice.” The Miltonon Spectator Published online Tue Feb 14 2012.
University of Alberta press release.
Email communication with Dr. William Yang.
- Marsha L. Miller, Ph.D., February 14, 2012